Iradimed Co (IRMD) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Iradimed Co stock $67.80, price $86.31, that is 21.4% below the price, quality 81 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $24.93 – $104.63 · fair‑value band $45.58 – $109.32 · the $86.31 price screens above the $67.80 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Iradimed Co in your weekly email
Every Wednesday you see whether Iradimed Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories.
Show moreShow less
The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers.
It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
Stock analysis
Iradimed Co (IRMD) currently trades at $86.31, while our model-based Fair Value estimate is $67.80, 21% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $47.67 per share, and 0 of the 26 models we run sit above the $86.31 price.
Bear case: the Dividend Discount group reads lowest at $15.78, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: $45.58 (bear) to $109.32 (bull), the price of $86.31 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 81/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Iradimed Co reported revenue of $83.8M in FY2025 versus $41.8M in FY2021, a compound +19.0%/yr. Reported net income was $22.5M in FY2025, compounding +24.6%/yr from FY2021.
Key figures
Market cap $1.1B Small · P/E ratio 46.2 · P/S ratio 12.4 · EPS (TTM) $1.87 · Dividend yield 0.9% · Net margin 26.9% · Return on equity 23.4% · Return on assets (EBIT) 19.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 86 out of 100 (medium confidence).
What moves the price
The share trades about 18% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −21%, IRMD screens richer than that median.
Fair Value models
Bear$45.58Fair Value $67.80Bull$109.32
Price $86.31 · Downside -21.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.9176 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 3 officers or directors sold shares worth $2.6M and none bought.
SaleMonty K AllenDirector2× since Feb 13, 2026: 2,419 shares, avg. $92.14$222,882Sep 3, 2026
SaleHilda Frederique Scharen-GuivelDirector3,000 shares at $95.00$285,000Jun 4, 2026
SaleRoger E. SusiCEO, President, Chairman, Director, 10% owner26× since Nov 10, 2025: 160,000 shares, avg. $93.89$15.0MJun 1, 202610b5-1 plan
SaleJohn GlennCHIEF FINANCIAL OFFICER2× since Nov 10, 2025: 25,651 shares, avg. $91.98$2.4MDec 11, 2025
SaleJames B HawkinsDirector2× since Nov 20, 2025: 6,000 shares, avg. $92.42$554,547Dec 9, 2025
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+14.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.5%
Start year 2020 (pandemic). Over 10 years: +10.2% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+27.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+26.7%
Dividend (yield on the price)0.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.18.7% vs 11.3%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−2% → 31%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+35.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+10.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +31.8% a year for the price and +8.2% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score81 · Top 25%
Fair Value upside−21.4% · Below median
Profitability
Return on equity (12 months)23.4% · Top 25%
Return on assets20.7% · Top 25%
Net margin (12 months)26.9% · Top 25%
Operating margin (12 months)33.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)14.2% · Above median
Dividend yield (12 months)0.9% · Bottom 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Iradimed Co Fair Value". https://www.fairvalue-calculator.com/stock/IRMD
Frequently asked questions
Is Iradimed Co (IRMD) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $67.80 versus a price of $86.31, about 21% lower (overvalued).
What is the fair value of IRMD?
Our model-based fair value for Iradimed Co is $67.80 (as of Nov 8, 2026), built from audited fundamentals. The current price: $86.31.
What is the quality score of IRMD?
Iradimed Co has a Quality Score of 81/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Iradimed Co (IRMD)?
Our model-based price target is the fair value of $67.80 (as of Nov 8, 2026) from 26 valuation models. Cautious scenario $45.58, optimistic scenario $109.32. It is a calculation from audited fundamentals, not an analyst target.
What is the Iradimed Co stock forecast for 2026?
Our models put fair value at $67.80, about 21% lower versus a price of $86.31 (overvalued). Cautious scenario $45.58, optimistic scenario $109.32. The calculation is refreshed regularly with new filings.
What is the revenue of Iradimed Co (IRMD)?
Iradimed Co reported trailing-twelve-month revenue of about $89.3M (latest available figure, as of Nov 8, 2026).
Does Iradimed Co pay a dividend?
Iradimed Co currently shows a dividend yield of 0.93% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Iradimed Co (IRMD) and when is the ex-dividend date?
Iradimed Co pays a dividend of $0.8 per share a year, a dividend yield of 0.9%. The last ex-dividend date was Aug 14, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 42.8% of earnings. Free cash flow covers the dividend 1.68 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Iradimed Co (IRMD)?
For today's price to be fair in a discounted-cash-flow model, Iradimed Co would have to grow free cash flow by +35.0 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +21.5 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of IRMD use?
Our models discount Iradimed Co at 11.0 %: a base by market capitalisation (small), damped by beta 0.91, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Iradimed Co that is +35.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Iradimed Co (IRMD) delivered so far?
Over the past 5 years revenue at Iradimed Co grew +21.5 % a year. The price currently implies free-cash-flow growth of +35.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Iradimed Co (IRMD) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Iradimed Co (+35.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Iradimed Co (IRMD)?
The free-cash-flow yield on the price is 1.55 %: that much free cash flow Iradimed Co produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Iradimed Co (IRMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Iradimed Co it is $67.80 per share (as of Nov 8, 2026), against a price of $86.31. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Iradimed Co stock overvalued or undervalued in 2026?
As of Nov 8, 2026, IRMD trades above its calculated fair value: price $86.31, fair value $67.80, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IRMD?
No. The price is what the market pays today ($86.31); the fair value is what the company's own numbers justify ($67.80). For Iradimed Co the two are $18.51 per share apart. That gap is exactly why we show both numbers side by side.
How much is Iradimed Co worth?
The market values Iradimed Co at about $1.1B (market capitalisation, as of Nov 8, 2026). Per share that is $86.31; our models calculate a fair value of $67.80 per share.
What do the bullish and bearish scenarios say about IRMD?
Our models span a range for Iradimed Co: cautious scenario $45.58, base $67.80, optimistic $109.32 per share (as of Nov 8, 2026, price $86.31). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IRMD?
Iradimed Co trades at a price-to-earnings ratio of 46.2 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $67.80 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, FY2023 ex one-offs: 42.0. Other multiples: PEG 4.5, P/B 11.7, P/S 12.4, EV/EBITDA 34.7.
What is the PEG ratio of IRMD?
The PEG ratio of Iradimed Co is 4.46 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Iradimed Co (IRMD)?
Balance-sheet figures for Iradimed Co (as of Nov 8, 2026): return on equity 23.4%. They feed the Quality Score of 81/100, which measures business quality independently of the share price.
How far is IRMD from its 52-week high?
Iradimed Co trades at $86.31, about 18% below its 52-week high of $104.63 and 13% above the low of $76.68 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $67.80 is for.
Which stocks are comparable to Iradimed Co?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Iradimed Co stock attractive at the current price?
The data as of Nov 8, 2026: price $86.31, calculated fair value $67.80 (−21%), Quality Score 81/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IRMD calculated?
We run Iradimed Co through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $67.80 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Iradimed Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Iradimed Co (IRMD)?
The closing price on Nov 6, 2026 was $86.31. Our model-based fair value is $67.80, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Iradimed Co right now?
A high-quality business (quality 81/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. A fairly wide model range ($45.58 to $109.32) leaves room in how you read the outcome.
Where does the earnings growth of Iradimed Co (IRMD) come from?
Earnings per share at Iradimed Co grew +13.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +10.9 %, EBIT margin −0.5 %, tax rate +2.1 %, residual (interest, one-offs) +0.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Iradimed Co
How large is the market capitalisation of Iradimed Co (IRMD)?
The market capitalisation of Iradimed Co is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Iradimed Co (IRMD)?
The price-to-sales ratio of Iradimed Co is 12.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Iradimed Co (IRMD)?
Earnings per share at Iradimed Co are $1.87 (price ÷ EPS = P/E 46.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Iradimed Co (IRMD)?
The dividend yield of Iradimed Co is 0.9% (payout 42.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Iradimed Co (IRMD)?
The net margin of Iradimed Co is 26.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Iradimed Co (IRMD)?
The return on equity (ROE) of Iradimed Co is 23.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Iradimed Co (IRMD)?
On an EBIT basis the return on assets of Iradimed Co is 19.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Iradimed Co (IRMD)?
The operating margin of Iradimed Co is 33.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Iradimed Co (IRMD)?
Revenue at Iradimed Co is growing +14.2% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Iradimed Co (IRMD)?
Earnings per share at Iradimed Co are growing +18.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Iradimed Co (IRMD) hold?
Iradimed Co holds more cash than debt, $51.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Iradimed Co in the live analysis
One click puts Iradimed Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026